InMed CEO, Eric A. Adams, is asked by Shadd Dales of The Dales Repot whether the cost of rare cannabinoids is scalable enough to entice big consumer product companies.
Read the article and watch the full video at The Dales Report.
InMed CEO, Eric A. Adams, is asked by Shadd Dales of The Dales Repot whether the cost of rare cannabinoids is scalable enough to entice big consumer product companies.
Read the article and watch the full video at The Dales Report.
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the role of the endocannabinoid system? How do cannabinoids interact with the
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What are illegal synthetic cannabinoids? How are illegal synthetic cannabinoids different from bioidentical synthesized
© Copyright 2023 InMed Pharmaceuticals Inc.
"*" indicates required fields